



ABIVAX to Participate in “Corporate Access” Event in San Francisco, January 8 – 10, 2018



PARIS, Dec. 21, 2017, 8:00 am. CET – ABIVAX (Euronext Paris: FR0012333284 – ABVX), a biotechnology company harnessing the immune system to develop a functional cure for HIV and treatments for inflammatory/autoimmune diseases and cancer, today announces that its senior management team will host institutional investor and partnering meetings at the LifeSci Advisors Corporate Access Event taking place in San Francisco, January 8-10, 2018.

To schedule a meeting with ABIVAX, investors can [register](#) on the online system managed by the Company’s US investor relations firm, [LifeSci Advisors, LLC](#), or make a request via e-mail at Access@LifeSciAdvisors.com.

About ABIVAX (www.abivax.com)

ABIVAX is mobilizing the body’s natural immune machinery to treat patients with viral infections, autoimmune diseases and cancer. A clinical-stage company, ABIVAX leverages its antiviral and immune enhancing platforms to optimize candidates to cure HIV and treat inflammatory bowel diseases and liver cancer. ABIVAX is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo : ABVX). More information on the company is available at www.abivax.com.

Follow us on Twitter [@ABIVAX_](https://twitter.com/ABIVAX_)



| | |
|---|---|
| ABIVAX Finance Didier Blondel didier.blondel@abivax.com +33 1 53 83 08 41 | Investors LifeSci Advisors Chris Maggos chris@lifesciadvisors.com +41 79 367 6254 |
| French Media ALIZE RP Caroline Carmagnol/Aurore Gangloff abivax@alizerp.com +33 6 64 18 99 59 / +33 1 44 54 36 65 | US Media LifeSci Public Relations Matt Middleman, M.D. matt@lifescipublicrelations.com +1 646 627 8384 |